Molecular dynamics simulations of asymmetric heterodimers of HER1/HER2 complexes

被引:0
|
作者
Chonticha Suwattanasophon
Napat Songtawee
Peter Wolschann
Kiattawee Choowongkomon
机构
[1] Kasertsart University,Department of Biochemistry, Faculty of Science
[2] Kasetsart University,Center for Advanced Studies in Tropical Natural Resources, National Research University
[3] Mahidol University,Kasetsart University
[4] University of Vienna,Department of Clinical Chemistry, Faculty of Medical Technology
[5] University of Vienna,Institute for Theoretical Chemistry
来源
关键词
HER family; Molecular dynamics simulation; Heterodimer; HER1; ErbB2;
D O I
暂无
中图分类号
学科分类号
摘要
The family of human epidermal growth factor receptors (HER) is involved in tumor cell growth. Homodimerization and heterodimerization of the HER family are important for activation of these receptors. The structures of homodimer conformation are well characterized, while the structures of heterodimer conformations, especially between HER1 and HER2, are not completely understood. In this study, two models of possible asymmetric HER1/HER2 kinase domains were built. Molecular dynamics simulations and molecular mechanics-Poisson-Boltzmann surface area (MM-PBSA) methods were applied to examine the possibility of these two-heterodimer interactions. From our results, it could be concluded that the HER2 kinase domain prefers to serve as the receiver rather than the activator. Key binding residues of this dimer complex at N lobe of HER2 is ALA683 and at C lobe of HER1 are GLU914, GLU917, and ASP930. This study will be useful in allowing us to predict and be able to control activity of this enzyme in disease in the future.
引用
收藏
相关论文
共 50 条
  • [31] The influence of hormone receptor status and HER1 and HER2 expression on the response to neoadjuvant therapy in breast cancer patients
    Bouiglieri, L.
    Torrisi, R.
    Pruneri, G.
    Colleoni, M.
    Viale, G.
    MODERN PATHOLOGY, 2008, 21 : 24A - 24A
  • [32] HER2 or not HER2: That is the question
    Burstein, HJ
    Winer, EP
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 3656 - 3659
  • [33] Preclinical adme evaluation of BMS-599626, a dual inhibitor of HER1 and HER2 receptor tyrosine kinases
    Zhang, Hongjian
    Yao, Ming
    Sleczka, Bogdan
    Davis, Carl
    Ryan, Patricia
    Iyer, Rama
    Marathe, Punit
    DRUG METABOLISM REVIEWS, 2006, 38 : 161 - 162
  • [34] Protein secretion in human mammary epithelial cells following HER1 receptor activation: influence of HER2 and HER3 expression
    Zhang, Yi
    Gonzalez, Rachel M.
    Zangar, Richard C.
    BMC CANCER, 2011, 11
  • [35] Protein secretion in human mammary epithelial cells following HER1 receptor activation: influence of HER2 and HER3 expression
    Yi Zhang
    Rachel M Gonzalez
    Richard C Zangar
    BMC Cancer, 11
  • [36] Computer-aided identification of novel anticancer compounds with a possible dual HER1/HER2 inhibition mechanism
    Elseginy, Samia A.
    Lazaro, Glorianne
    Nawwar, Galal A. M.
    Amin, Kamilia M.
    Hiscox, Stephen
    Brancale, Andrea
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2015, 25 (04) : 758 - 762
  • [37] The influence of hormone receptor status and HER1 and HER2 expression on the response to neoadjuvant therapy in breast cancer patients
    Bonigliere, L.
    Torrisi, R.
    Pruneri, G.
    Colleoni, M.
    Viale, G.
    LABORATORY INVESTIGATION, 2008, 88 : 24A - 24A
  • [38] Histopathologic and immunohistochemical findings of skin rash to HER1 and HER1/2 inhibitors during anticancer therapy
    Nardone, B.
    Kaklamani, V. G.
    Nicholson, K. M.
    Newman, M.
    Guitart, J.
    Gerami, P.
    Talarico, N.
    Rademarker, A.
    West, D. P.
    Lacouture, M. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [39] HER1, HER2, HER3 and HER4 gene copy number and protein expression in non-small cell lung cancer
    Jeon, Y.
    Kim, Y.
    Sung, S.
    Seo, J.
    Chung, D.
    HISTOPATHOLOGY, 2008, 53 : 350 - 350
  • [40] MEK inhibition leads to elevated HER3:PI3K in EGFR or HER2 driven cancer through feedback induction of HER1:3 and HER2:3 dimers
    Hoe, Nicholas
    Mateling, Michael
    Ma, Yating
    Jin, Kelly
    Zhou, JinYao
    Kirkland, Richard
    Kuy, Crystal
    Liu, Xinjun
    Kim, Phillip
    Singh, Sharat
    CANCER RESEARCH, 2013, 73 (08)